LuxTrust and Cambridge Blockchain Announce Private Beta for Privacy-Protecting Identity Platform IDKEEP
16.7.2019 13:00:00 EEST | Business Wire | Press release
LuxTrust S.A., a leading Digital Trust Services Provider in Luxembourg, and Cambridge Blockchain Inc. , a pioneer in digital identity enterprise Software, announced the private beta-testing phase for privacy-protecting European identity platform IDKEEP .
Designed to resolve identity and personal-data related challenges faced by many digital service providers — such as banks and financial services, insurance, and healthcare, among others—IDKEEP is a huge step forward towards data ownership and control. The platform provides end users with full control over personal data and over sharing such data with services online, helping digital organizations to effectively manage consent as per GDPR rules and effectively manage validated users’ data, enabling trusted transactions online. In addition, IDKEEP opens a marketplace for data validators who can leverage a network effect of a large customer base, realizing efficiencies and re-use of expensive data validation processes.
IDKEEP was developed by LuxTrust in Luxembourg to augment the intrinsic value of existing digital identities which already take up the entire population of the country, and to foster a data-driven business ecosystem. With IDKEEP, LuxTrust combines its role of eIDAS Qualified Trust Services Provider, with a GDPR trusted third-party role. Supported by the Luxembourg State, one of company’s shareholders as well as a strategic partnership with InfoCert (Italy), IDKEEP leads the way towards a new age of digital identity.
IDKEEP has been showcased in Seoul, South Korea today, in presence of Luxembourg’s Deputy Prime Minister and Minister of the Economy, Étienne Schneider, thereby initiating a beta-testing phase. Étienne Schneider said: “With the introduction of its IDKEEP solution, LuxTrust shows off its skills and competencies when it comes to play a leading role as an innovation-driven company. The platform asserts LuxTrust’s position as a forerunner among digital identity providers. Technological developments like IDKEEP help to achieve the digital economy of tomorrow and contribute to Luxembourg’s reputation in Europe and beyond as a trusted data hub”.
IDKEEP platform runs on Cambridge Blockchain’s innovative blockchain-based enterprise software, a first-of-its-kind technology that gives users back control of their own identity by increasing data quality, re-usability, and trust. “After receiving investments from PayPal (NASDAQ:PYPL), Flourish and Omidyar Network earlier this year, we are pleased to continue our expansion to deliver the future of digital identity for Europe and beyond.” said Matthew Commons, CEO and cofounder of Cambridge Blockchain.
This announcement is an important milestone toward the resolution of digital identity challenges. IDKEEP is now signing up additional trusted parties and service providers. Organizations interested in joining the platform should please contact Povilas Žinys: povilas.zinys@luxtrust.lu
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190716005351/en/
Contact information
Povilas Žinys
povilas.zinys@luxtrust.lu
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom